Abstract
Neuroendocrine tumors (NET) have several distinct pathophysiological features that can be addressed by specific radiolabeled probes. An overview on the different radiopharmaceuticals that have been developed for positron emission tomography (PET) of NET are presented. The focus is on fluordeoxyglucose (F-18 FDG), biogenic amine precursors, somatostatin analogs, and hormone syntheses markers. Due to the highly specific tracers lacking any clear anatomical landmarking, the advantages of integrated functional and morphological imaging systems such as PET-CT are obvious. Based on the up to now published literature and one’s own experience, it is concluded that amine precursors (e.g. fluor-dihydroxyphenylalanin and hydroxytryptophane) should be employed in most gastroenteropancreatic NET, whereas F-18 FDG should be preserved for more aggressive less-differentiated NETs. Hormone syntheses markers have up to now only been used in few centers and their broad clinical value remains uncertain. The different available somatostatin analogs are the most promising tracers, since they can improve dosimetry in cases where peptide receptor radiotherapies are planned. Of specific interest are the somatostatin analogs addressing several subtypes of the somatostatin receptor (e.g. DOTANOC) that allow detecting also subtypes not expressing the “classically” addressed subtype 2 and 5. Since NET have a high variety of different features, the individual diagnostic approach using PET or integrated PET-CT should be tailored, depending on the histological classification and the differentiation of the tumor.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Sundin, A., Garske, U., Örlefors, H. (2007) Nuclear imaging of neuroendocrine tumors Best Pract Res Clin Endocrinol Metab 21, 69–85.
Pearse, A.G. (1968). Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin Proc R Soc Lond B Biol Sci 170(18), 71–80.
Pearse, A.G. (1980). The APUD concept and hormone production Clin Endocrinol Metab 9(2), 211–22.
Reubi, J.C. (2003). Peptide receptors as molecular targets for cancer diagnosisand therapy Endocr Rev 24(4), 389–427.
Patel, R.C., Kumar, U., Lamb, D.C.,et al.(2002) Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells Proc Natl Acad Sci U S A 99(5), 3294–9.
Patel, Y.C., Greenwood, M.T., Panetta, R., Demchyshyn, L., Niznik, H., Srikant, C.B. (1995) The somatostatin receptor family Life Sci 57(13), 1249–65.
Williams, E.D., Sandler, M. (1963) The classification of carcinoid tumors Lancet 1, 238–9.
Solcia, E., Klöppel, G., Sobin, L. (2000) Histological typing of endocrine tumors, 2nd edition. Berlin, Heidelberg Springer Verlag.
Pacak, K., Eisenhofer, G., Goldstein, D.S. (2004) Functional imaging of endocrine tumors: role of positron emission tomography Endocr Rev 25(4), 568–80.
Lamberts, S.W., Bakker, W.H., Reubi, J.C., Krenning, E.P. (1990) Somatostatin-receptor imaging in the localization of endocrine tumors N Engl J Med 323(18), 1246–9.
Brown, R.S., Wahl, R.L. (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study Cancer 72(10), 2979–85.
Adams, S., Baum, R.P., Hertel, A., Schumm-Drager, P.M., Usadel, K.H., Hor, G. (1998)Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiatedtumors: comparison with the expression of the Ki-67 antigen Nucl Med Commun 19(7), 641–7.
Adams, S., Baum, R., Rink, T., Schumm-Drager, P.M., Usadel, K.H., Hor, G. (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors Eur J Nucl Med 25(1), 79–83.
Hoegerle, S., Altehoefer, C., Ghanem, N., Brink, I., Moser, E., Nitzsche, E. (2001) 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels Eur J Nucl Med 28(1), 64–71.
Kok, J., Lin, M., Wong, V., et al. (2008) (18F)FDG PET-CT in pancreatic neuroendocrine tumors associated with von Hippel Lindau Syndrome Clin Endocrinol 70(4), 657–9.
Belhocine, T., Foidart, J., Rigo, P., et al. (2002) Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumors: correlations with the pathological indexes p53 and Ki-67 Nucl Med Commun 23, 727–34.
Diehl, M., Risse, J.H., Brandt-Mainz, K., et al. (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer:results of a multicentre study Eur J Nucl Med 28:(11), 1671–6.
Szakall, S., Jr., Esik, O., et al. (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma J Nucl Med 43(1), 66–71.
Rubello, D., Rampin, I., Nanni, C., et al. (2008) The role of 18F-FDG PET-CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective study Eur J Surg Oncol 34, 581–6.
Ong, S.C., Schröder, H., Patel, S.G., et al. (2007) Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels J Nucl Med 48, 501–7.
Rufini, V., Treglia, G., Perotty, G., et al. (2008) Role of PET in medullary thyroid carcinoma Minerva Endocrinol 33, 67–73.
Orlefors, H., Sundin, A., Garske, U.,et al. (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography J Clin Endocrinol Metab 90(6), 3392–400.
Hoegerle, S., Altehoefer, C., Ghanem, N.,et al.(2001) Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors Radiology 220(2), 373–80.
Becherer, A., Szabo, M., Karanikas, G., et al. (2004) Imaging of advanced neuroendocrine tumors with (18)F-DOPA PET J Nucl Med 45, 1161–7.
Hoegerle, S., Nitzsche, E., Altehoefer, C., et al.(2002) Pheochromocytomas: detection with 18F DOPA whole body PET – initial results Radiology 222(2), 507–12.
Hoegerle, S., Ghanem, N., Altehoefer, C.,et al.(2003) 18F-DOPA positron emission tomography for the detection of glomus tumors Eur J Nucl Med Mol Imaging 30(5), 689–94.
Örlefors, H., Sundin, A., Ahlström, H., et al. (1998) Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors J Clin Oncol 16, 2534–42.
Sundin, A., Eriksson, B., Bergström, M., et al. (2004) PET in the diagnosis ofneuroendocrine tumors Ann NY Acad Sci 1014, 246–57.
Orlefors, H., Sundin, A., Lu, L.,et al.(2006) Carbidopa pretreatment improves image interpretation and visualization of carcinoid tumors with 11C-5-hydroxytryptophan positron emission tomography Eur J Nucl Med Mol Imaging 33(1), 60–5.
Koopmans, K., Neels, O., Kema, I., et al. (2008) Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-Phenyl-alanine and 11C-5-Hydroxy-Tryptophan positron emission tomography J Clin Oncol 26, 1489–1495.
Ilias, I., Yu, J., Carrasquillo, J.A.,et al. (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma J Clin Endocrinol Metab 88(9), 4083–7.
Ilias, I., Chen, C.C., Carrasquillo, J.A., et al. (2008) Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49(10), 1613–9.
Kaji, P., Carrasquillo, J.A., Linehan, M.W., et al. (2007) The role of 6-(18F)fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome Eur J Endocrinol 156, 483–7.
Shulkin, B.L., Wieland, D.M., Schwaiger, M.,et al.(1992) PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma J Nucl Med 33(6), 1125–31.
Trampal, C., Engler, H., Juhlin, C., Bergstrom, M., Langstrom, B. (2004) Pheochromocytomas: detection with 11C hydroxyephedrine PET Radiology 230(2), 423–8.
Mann, G.N., Link, J.M., Pham, P.,et al.(2006) [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma Ann Surg Oncol 13(2), 187–97.
Bergstrom, M., Bonasera, T.A., Lu, L.,et al.(1998) In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors J Nucl Med 39(6), 982–9.
Bergstrom, M., Juhlin, C., Bonasera, T.A.,et al.(2000) PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate J Nucl Med 41(2), 275–82.
Hennings, J., Lindhe, O., Bergstrom, M., Langstrom, B., Sundin, A., Hellman, P. (2006) [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings J Clin Endocrinol Metab 91(4), 1410–4.
Hennings, J., Hellman, P., Ahlström, H., et al. (2007) Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas Eur J Radiol 69(2), 314–23.
Oliveira, P.G., Brenol, C.K., Edelweiss, M. et al. (2008) Effect of an antagonist of the bombesin/gastrin releasing peptide receptor on complete Freund’s adjuvant-induced arthritis in rats Peptides 29(10),1726–31.
Krenning, E.P., Bakker, W.H., Breeman, W.A.,et al. (1989) Localization of endocrine-related tumors with radioiodinated analogue of somatostatin Lancet 1(8632), 242–4.
Valkema, R., Pauwels, S., Kvols, L.K.,et al.(2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors Semin Nucl Med 36(2), 147–56.
Antunes, P., Ginj, M., Zhang, H., et al. (2007) Are radiogallium-labelled DOTA- conjugated somatostatin analogues superior to those labeled with other radiometals Eur J Nucl Med Mol Imaging 34(7), 982–93.
Henze, M., Schuhmacher, J., Hipp, P.,et al.(2001) PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas J Nucl Med 42(7), 1053–6.
Hofmann, M., Maecke, H., Borner, R.,et al.(2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data Eur J Nucl Med 28(12), 1751–7.
Kowalski, J., Henze, M., Schuhmacher, J., Macke, H.R., Hofmann, M., Haberkorn, U. (2003)Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors Mol Imaging Biol 5(1), 42–8.
Henze, M., Dimitrakopoulou-Strauss, A., Milker-Zabel, S.,et al.(2005) Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas J Nucl Med 46(5), 763–9.
Buchmann, I., Henze, M., Engelbrecht, S.,et al.(2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumors Eur J Nucl Med Mol Imaging 34(10), 1617–26.
Fanti, S., Ambrosini, V., Tomassetti, P., et al. (2008) Evaluation of unusual neuroendocrine tumors by means of 68Ga-DOTA-NOC PET Biomed Pharmacother 62, 667–71.
Ambrosini, V., Tomassetti, P., Castellucci, P., et al. (2008) Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumors Eur J Nucl Med Mol Imaging 35, 1431–8.
Von Schulthess, G.K., Steinert, H.C., Hany, T.F. (2006) Integrated PET-CT: current applications and future directions. Radiology 238(2), 405–22.
Mottaghy, F.M., Sunderkotter, C., Schubert, R.,et al.(2007) Direct comparison of[18F]FDG PET-CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma Eur J Nucl Med Mol Imaging 34(9), 1355–64.
Beyer, T., Townsend, D.W., Brun, T.,et al.(2000) A combined PET-CT scanner for clinical oncology J Nucl Med 41(8), 1369–79.
Mottaghy, F.M., Reske, S.N. (2006) Func-tional imaging of neuroendocrine tumors with PET Pituitary 9(3), 237–42.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Humana Press
About this protocol
Cite this protocol
Van Binnebeek, S., Karges, W., Mottaghy, F.M. (2011). Functional Imaging of Neuroendocrine Tumors. In: Juweid, M., Hoekstra, O. (eds) Positron Emission Tomography. Methods in Molecular Biology, vol 727. Humana Press. https://doi.org/10.1007/978-1-61779-062-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-61779-062-1_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-061-4
Online ISBN: 978-1-61779-062-1
eBook Packages: Springer Protocols